Oscar Health, Inc. (OSCR) Stock Sinks As Market Gains: What You Should Know
The latest trading day saw Oscar Health, Inc. (OSCR) settling at $31.44, representing a -2.3% change from its previous close.
OSCR - Oscar Health, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$24.20
DETAILS
HIGH:
$35.00
LOW:
$16.00
MEDIAN:
$20.00
CONSENSUS:
$24.20
DOWNSIDE:
21.30%
Stock News
Oscar Health, Inc. (OSCR) Stock Dips While Market Gains: Key Facts
Oscar Health, Inc. (OSCR) closed at $28.52 in the latest trading session, marking a -3.16% move from the prior day.
Oscar Health, Inc. (OSCR) Declines More Than Market: Some Information for Investors
Oscar Health, Inc. (OSCR) concluded the recent trading session at $29.16, signifying a -2.57% move from its prior day's close.
Oscar Health Inc (OSCR) Stock Up 4.9% but GF Value Says Overvalued -- GF Score: 79/100
On June 23, 2026, Oscar Health Inc (OSCR) shares rose 4.9% to a current price of $29.93, reflecting a strong performance in the market. The stock has experience
A Look at Oscar Health Inc (OSCR) After 3.1% Gain -- GF Value $20.91 vs Price $29.14
On June 15, 2026, Oscar Health Inc (OSCR) shares rose 3.1% to $29.14, continuing a strong upward trend with a remarkable year-to-date increase of 102.8%. The st
This Little-Known Healthcare Stock Is Up 90% This Year, and the Party Might Just Be Getting Started
Oscar Health is gaining a ton of share in the health insurance space. The company is aiming for a huge profit boost this year.
Oscar Health, Inc. (OSCR) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Oscar Health, Inc. (OSCR) settling at $28.26, representing a -2.25% change from its previous close.
Oscar Health Stock In Focus: 52-Week High, Goldman Sachs Conference, Q1 Earnings
Oscar Health, Inc. (NYSE:OSCR) shares are touching fresh 52-week highs Wednesday, extending a remarkable 80% year-to-date run as investors digest Monday's guidance reaffirmation at the Goldman Sachs Healthcare Conference.
Oscar Health, Inc. (OSCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Oscar Health, Inc. (OSCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Oscar Health, Inc. (OSCR) Just Overtook the 20-Day Moving Average
From a technical perspective, Oscar Health, Inc. (OSCR) is looking like an interesting pick, as it just reached a key level of support. OSCR recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Oscar Health vs. UnitedHealth: Which Healthcare Stock Is a Better Buy in 2026?
Oscar Health's tech-driven growth contrasts with UnitedHealth's massive scale and diversified revenue.
This Magnificent Stock Could Deliver Market‑Beating Returns for Years
Investors are still underappreciating the potential for this healthcare company's growth.
This Top Stock Looks Too Cheap to Ignore
Shares trade up 53% so far in 2026, but they are still underappreciated by investors.
3 Stocks I Plan to Hold for the Next 20 Years
Nintendo is a durable brand in family entertainment. Oscar Health has a long runway to grow in health insurance.
After Golden Cross, Oscar Health, Inc. (OSCR)'s Technical Outlook is Bright
Oscar Health, Inc. (OSCR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OSCR's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
How Oscar Health Is Reinventing Healthcare
Oscar Health is an ACA insurer who leans into the individual plans it can provide. The company's network is key to keeping costs low and creating an incentive to stay in the ecosystem.
MURGY vs. OSCR: Which Stock Is the Better Value Option?
Investors looking for stocks in the Insurance - Multi line sector might want to consider either M?nchener R?ckversicherungs-Gesellschaft (MURGY) or Oscar Health, Inc. (OSCR). But which of these two stocks is more attractive to value investors?
Oscar Health, Inc. (OSCR) Q1 2026 Earnings Call Transcript
Oscar Health, Inc. (OSCR) Q1 2026 Earnings Call Transcript
Oscar Health Earnings Review: The Best Q1 Scenario We Could Hope For
Oscar Health (OSCR) delivered a standout Q1 2026, with $4.65B revenue, 52.7% YoY growth, and a 70.5% medical loss ratio. I reaffirm my Strong Buy rating and raise the 2026 price target to $30, citing robust execution and guidance reaffirmation. OSCR's SG&A leverage and technology platform drove operating efficiency, with Q1 Adjusted EBITDA at $727.1M and SG&A ratio likely below 15.8%.
Oscar Health, Inc. (OSCR) Beats Q1 Earnings Estimates
Oscar Health, Inc. (OSCR) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $0.92 per share a year ago.
Price Targets
Raymond James on Court Ruling: 'This should be viewed as a positive OSCR and other ACA exchange players as this puts to bed the $5 rule'
$30.00
(was $28.13)
John Ransom
·
Raymond James
Barclays Upgrades Oscar Health Inc (OSCR) to Overweight, 'we see a visible path to an undemanding 13–15x P/E valuation'
$35.00
(was $27.22)
Andrew Mok
·
Barclays
Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight
$20.00
(was $20.50)
Stephen Baxter
·
Wells Fargo
Oscar Health price target raised to $30 from $21 at Barclays
$30.00
(was $21.70)
Barclays
Oscar Health price target raised to $20 from $15 at UBS
$20.00
(was $19.84)
Jonathan Yong
·
UBS
Oscar Health price target raised to $21 from $18 at Barclays
$21.00
(was $19.84)
Barclays
Oscar Health upgraded to Hold from Underperform at Jefferies
$16.00
(was $15.79)
David Windley
·
Jefferies
Oscar Health upgraded to Outperform from Market Perform at Raymond James
$18.00
(was $13.60)
Raymond James
Oscar Health price target lowered to $15 from $17 at UBS
$15.00
(was $13.56)
Jonathan Yong
·
UBS
Oscar Health upgraded to Neutral from Sell at UBS
$17.00
(was $16.90)
UBS
Oscar Health upgraded to Equal Weight from Underweight at Barclays
$18.00
(was $14.97)
Andrew Mok
·
Barclays
Oscar Health initiated with a Neutral at Goldman Sachs
$17.00
(was $20.40)
Goldman Sachs
Oscar Health price target raised to $14 from $10 at Wells Fargo
$14.00
(was $22.31)
Wells Fargo
Oscar Health price target lowered to $13 from $14 at Piper Sandler
$13.00
(was $14.64)
Jessica Tassan
·
Piper Sandler
Oscar Health Inc (OSCR) PT Raised to $28 at Piper Sandler
$28.00
(was $18.38)
Jessica Tassan
·
Piper Sandler
Piper Sandler Starts Oscar Health Inc (OSCR) at Overweight
$25.00
(was $17.64)
Jessica Tassan
·
Piper Sandler
Oscar Health price target raised to $27 from $24 at Wells Fargo
$27.00
(was $20.01)
Stephen Baxter
·
Wells Fargo
Goldman Sachs Reiterates Neutral Rating on Oscar Health Inc (OSCR)
$21.00
(was $20.21)
Nathan Rich
·
Goldman Sachs
Raymond James Starts Oscar Health Inc (OSCR) at Outperform
$20.00
(was $13.76)
John Ransom
·
Raymond James
Oscar Health upgraded to Overweight from Equal Weight at Wells Fargo
$4.00
(was $2.89)
Stephen Baxter
·
Wells Fargo